Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance
Amneal Pharmaceuticals (AMRX) has seen a 345.7% return over the past three years, leading to a valuation that appears fairly priced rather than an obvious bargain. While strong Q2 2026 results and raised full-year guidance support the current valuation, the stock trades at a P/E ratio of 37.1x, above the industry average, suggesting that much of the good news may already be factored in. The stock's future performance hinges on its ability to sustain strong earnings and margin growth to justify its premium valuation.
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity
Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised fund on the same date. Following these transactions, Kiely directly holds 200,252 shares of Class A Common Stock.
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026
John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company stands at 200,252 shares. The details were revealed in a Form 4 filing on August 14, 2026.
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings
Amneal Pharmaceuticals director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on August 11, 2026. The shares were sold at a weighted average price of $17.18, with individual trades ranging from $17.07 to $17.31. Following this transaction, Buchi indirectly holds 93,499 shares through a trust and directly holds 75,077 shares.
What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders
Amneal Pharmaceuticals (AMRX) has raised its guidance for the second half of 2026, driven by a strategic pivot towards higher-value complex generics, biosimilars, and specialty medicines. Despite ongoing generic pricing pressures, the company projects significant revenue and earnings growth by 2029, with analysts anticipating a substantial upside to its current stock price. This shift aims to improve profitability and manage its debt load, though sustained success depends on new product launches and biosimilar approvals.
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades
Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold a total of 216,613 shares of Class A Common Stock in two separate transactions on August 11 and August 12, 2026. The sales were open-market transactions, not pursuant to a Rule 10b5-1 trading plan, and involved weighted average prices of $17.70 and $17.40 per share respectively. Following these transactions, Daly's direct holdings in Class A Common Stock are 35,171 shares.
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A
Tushar Patel has filed an Amendment No. 6 to his Schedule 13D, disclosing beneficial ownership of 61,341,678 shares of Amneal Pharmaceuticals Class A common stock, representing 17.6% of the outstanding shares. This updated ownership stake reflects shares acquired through the recent Kashiv BioSciences acquisition, where Amneal issued 28,942,098 Class A shares to sellers, including those attributed to Patel. Patel's beneficial ownership includes holdings by TI SIE 2 and Rock Nola, LLC, an entity controlled by a trust associated with him.
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares
Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC for $375 million in cash and 28,942,098 shares of Class A Common Stock. This transaction has resulted in Chintu Patel becoming the beneficial owner of 32,576,528 shares, representing 9.4% of Amneal's Class A Common Stock. The filing details Patel's direct and indirect holdings, including shares held through trusts and entities like CKR Dynasty, LLC and Shivkan Holdings, LLC, which received a portion of the newly issued shares.
Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal
Amneal Pharmaceuticals' Co-CEO, Chirag K. Patel, through entities he manages, acquired 6,381,734 Class A common shares on August 10, 2026. This share issuance was part of Amneal's acquisition of Kashiv BioSciences, LLC. After the transaction, Patel holds 1,393,470 shares directly and 21,269,420 shares indirectly through family trusts, in addition to the newly acquired shares via LLCs.
Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal
Amneal Pharmaceuticals director Gautam Patel reported an indirect acquisition of 283,632 Class A common shares on August 10, 2026. These shares were received by limited liability companies he manages as part of Amneal's acquisition of Kashiv BioSciences, LLC. Following this transaction, Patel directly holds 1,643,963 shares of Amneal.
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality
Amneal Pharmaceuticals reported healthy earnings, but the stock price remained stable. The company's profit was impacted by US$81m in unusual expenses, which are likely one-off events, suggesting higher future profits. The article highlights that these unusual items might cause Amneal Pharmaceuticals' statutory profit to understate its true earnings potential and advises investors to consider other factors like margins and growth.
UBS raises Amneal Pharmaceuticals price target on biosimilar growth
UBS has increased its price target for Amneal Pharmaceuticals Inc. to $25.00 from $23.00, maintaining a Buy rating. This adjustment follows the company's strong second-quarter earnings beat and raised guidance, despite a recent stock pullback. UBS anticipates significant growth from Amneal's biosimilar and generic product approvals, with new launches expected to add $1 billion to $2 billion in incremental revenue by 2030.
Amneal Pharma A earnings beat by $0.07, revenue topped estimates
Amneal Pharma A (NASDAQ: AMRX) reported strong second-quarter results, surpassing analyst estimates with EPS of $0.300 and revenue of $796.2 million. The company also provided optimistic full-year 2026 guidance, expecting EPS between $0.960-$1.060 and revenue between $3.100B-$3.200B. AMRX stock has shown significant growth, increasing by 48.870% in the last 3 months and 144.250% in the last 12 months.
Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure
Amneal Pharmaceuticals (AMRX) reported a strong Q2 with increased revenue and adjusted EPS, leading to a raised full-year outlook. While the company is transitioning towards higher-margin biosimilars and injectables, investor concern centers on the sustainability of this profit momentum given increased capital expenditure and the need to close and realize benefits from the Kashiv deal. Bulls highlight execution proof points in their shift to higher-value assets, while bears focus on timing, leverage, and capacity risks, questioning if the current spending and insider selling are isolated issues or deeper strains.
Earnings call transcript: Amneal tops Q2 2026 estimates, but shares slip
Amneal Pharmaceuticals reported stronger-than-expected Q2 2026 earnings and revenue, with adjusted EPS at $0.30 and revenue at $796.2 million, beating analyst estimates. Despite the strong performance and raised full-year guidance, the stock saw a slight premarket dip, potentially due to its proximity to its 52-week high and elevated investor expectations. The company highlights robust growth in affordable medicines and specialty segments, expansion into biosimilars, and progress in its GLP-1 manufacturing partnership with Pfizer as key long-term drivers.
Amneal Reports Second Quarter 2026 Financial Results
Amneal Pharmaceuticals reported strong second-quarter 2026 financial results, with net revenue increasing 10% to $796 million and diluted EPS rising 157% to $0.18. The company is raising its full-year 2026 guidance, driven by growth in its Specialty and Affordable Medicines segments and successful debt repricing. Amneal also highlighted the upcoming Kashiv acquisition, expected to establish biosimilars as a new growth area.
Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?
Amneal Pharmaceuticals (AMRX) recently received FDA approval for additional strengths and vial sizes of its iohexol injection, boosting its product portfolio and contributing to strong share price momentum. While analysts consider the stock about 5% overvalued with a fair value of $18.25, Simply Wall St's DCF model suggests it is significantly undervalued at $53.36. Investors are advised to review the underlying data and consider both the potential rewards and risks, including generic pricing pressures and competition.
Amneal Reports Second Quarter 2026 Financial Results
Amneal Pharmaceuticals reported strong second quarter 2026 financial results with net revenue up 10% to $796 million and adjusted EBITDA increasing 12% to $206 million. The company raised its full-year 2026 guidance, citing broad-based performance and confidence in its diversified portfolio, including anticipated contributions from the Kashiv biosimilars transaction. Amneal also announced a successful debt repricing expected to reduce annual interest costs and contribute to its goal of reducing net leverage.
Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD
Amneal Pharmaceuticals stock (AMRX) recently hit a 52-week high of $18.59, reflecting a 123.61% increase over the past year. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q1 2026 results and received FDA approvals for new products, including a romidepsin injection solution and additional iohexol injection strengths, alongside positive interim results from its CREXONT Parkinson's disease study.
Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD By Investing.com
Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $18.59, reflecting a 123.61% increase over the past year. The company recently reported strong Q1 2026 financial results, surpassing earnings and revenue expectations, and received FDA approvals for new products, including romidepsin injection and additional strengths of iohexol injection. InvestingPro analysis suggests the stock is currently overvalued, yet these developments highlight Amneal's growth and pipeline advancements.
Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT
Amneal Pharmaceuticals, Inc. Class A (FWB:2DT) generated 2.57 billion EUR last year, with its Affordable Medicines segment being the top performer contributing 1.49 billion EUR. The primary revenue sources by region were the United States, India, and Ireland. The company's total revenue saw a decrease from 2.70 billion EUR in the previous year.
How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats
Amneal Pharmaceuticals has received FDA approval for additional strengths and vial sizes of its iohexol injection, making it the first generic supplier for various OMNIPAQUE-referenced presentations. This expansion reinforces Amneal's injectable and hospital portfolio, potentially supporting its revenue and earnings forecasts, but also highlights risks related to margin pressure, debt, and the need for strong execution against its 2026 guidance. Investors should consider how this move impacts the company's broader investment narrative and financial outlook.
Amneal Pharmaceuticals (AMRX) Stock May Be Fully Priced Following Its 4.7x Run
Amneal Pharmaceuticals (AMRX) has experienced a significant 4.7x share price increase over the last three years, leading to a valuation that appears expensive compared to industry averages. Despite recent FDA approval for its iohexol injection portfolio, the stock's current P/E ratio of 46.8x is more than double the industry average, suggesting it may be overvalued. The article raises questions about whether future earnings and margins can justify the current high expectations reflected in its stock price.
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
President Donald Trump has introduced a policy requiring generic drug manufacturers to build U.S. capacity within two years or face escalating tariffs of up to 200%. This move aims to reshore generic pharmaceutical production, contrasting with the treatment of branded medicines. The policy presents challenges for generic producers due to their low-price business model and the complexities of relocating manufacturing, potentially leading to drug shortages or higher costs. Certain U.S.-based companies like Amgen, AbbVie, and Gilead, and those with significant domestic manufacturing like Amphastar and ANI Pharmaceuticals, are better positioned to navigate these changes.
ETFs Investing in Amneal Pharmaceuticals, Inc. Class A Stocks
This article lists various ETFs that include Amneal Pharmaceuticals, Inc. Class A stocks in their holdings. The data presented for each ETF includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return, offering a comprehensive overview for investors.
AMRX: Amneal Pharmaceuticals Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas
This article provides current stock information for Amneal Pharmaceuticals Inc (AMRX), including its latest stock price, market capitalization, volume, and key financial ratios. It also highlights recent news from Zacks indicating AMRX as a strong growth and momentum stock, along with discussions about other trending stocks like GOOGL, SMCI, and RKLB.
How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story
Amneal Pharmaceuticals recently received FDA approval for additional strengths and vial sizes of its iohexol radiographic contrast injection, becoming the first generic version referencing OMNIPAQUE across these presentations. This expands Amneal's reach in a US$706 million market and supports its strategy of leaning on higher-value generics and specialty-type products to meet revenue guidance, though risks like pricing pressure and debt management remain. The new approvals could influence analyst views, with some already projecting significant revenue and earnings growth for the company by 2029.
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com
Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $17.86, trading at $17.87 with a market capitalization of $5.65 billion. This milestone follows a 116.75% increase over the past year, driven by strong financial performance including Q1 2026 EPS of $0.27 and revenue of $723 million, and key product advancements like FDA approval for its romidepsin injection solution and positive interim results from its Parkinson’s drug study. InvestingPro data indicates a "GREAT" financial health score and that the stock is trading near its Fair Value.
Amneal gains FDA approval for four iohexol products
Amneal Pharmaceuticals received FDA approval for four new iohexol injection presentations, including three 350 mg iodine/mL vial sizes, expanding its generic contrast-agent portfolio. These products, targeting a $706 million U.S. market, are the first generic versions referencing OMNIPAQUE across these approved presentations. Amneal plans to launch them in Q3 2026, and its shares rose 4.88% following the announcement.
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD
Amneal Pharmaceuticals Inc. Class A stock recently reached a new 52-week high of $17.86, reflecting a significant 116.75% increase over the past year. This milestone follows strong first-quarter 2026 financial results, with EPS and revenue surpassing expectations, alongside key FDA approval for its romidepsin injection and positive interim results from its Parkinson's drug study.
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating?
Amneal Pharmaceuticals (AMRX) has experienced a significant rerating with strong short-term and long-term shareholder returns. While analysts consider it slightly undervalued at $18.25, a Discounted Cash Flow (DCF) model suggests a much higher fair value of $53.36, indicating potential undervaluation. The article highlights strategic growth initiatives and potential risks, advising investors to review the numbers and decide which valuation approach is most realistic.
Amneal Pharmaceuticals (AMRX) Proxy filing Summary
This article summarizes Amneal Pharmaceuticals' (AMRX) proxy filing regarding its acquisition of Kashiv BioSciences, LLC. The acquisition involves issuing 28,942,108 shares of Class A common stock and $375 million in cash, plus potential milestone payments, aiming to expand Amneal's biosimilars platform and diversify growth. Shareholders will vote on approving the transaction and stock issuance, both of which are critical for the deal to proceed.
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?
Amneal Pharmaceuticals received a positive opinion from the EMA for its Parkinson’s drug, Hopledo, which supports the company's shift towards higher-value neurology drugs away from its U.S. generics base. While this regulatory milestone expands Amneal's branded neurology footprint, the company still faces challenges including high leverage and pricing pressure in the generics market. The article suggests that despite the positive news, investors need to consider these existing risks and evaluate the company's long-term financial health.
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced?
Amneal Pharmaceuticals (AMRX) recently received a positive EU opinion for Hopledo, a Parkinson's disease therapy, contributing to its strong share price performance. While a discounted cash flow model suggests it's undervalued with a fair value of $17.25, its P/E ratio of 44.8x indicates it's expensive compared to industry averages and peers. Investors are advised to consider both the underlying data and potential risks like generics pricing pressure and biosimilar execution before making investment decisions.
Price to sales forward of Amneal Pharmaceuticals, Inc. Class A – SWB:2DT
This article provides the "Price to sales forward" value for Amneal Pharmaceuticals, Inc. Class A (SWB:2DT) on the Stuttgart Stock Exchange. It notes that the market is currently closed with no trades. The content primarily focuses on financial data for this specific company.
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The FDA announced that Eli Lilly, Regeneron, and five other companies have been selected for its PreCheck Pilot Program. This initiative aims to bolster domestic pharmaceutical manufacturing and improve the resilience of the U.S. drug supply chain by providing early regulatory engagement for new U.S. production facilities. The program is part of a broader effort to provide a predictable regulatory pathway for companies wishing to manufacture medicines in the U.S. and ensure access to critical therapies, reflecting the administration's goal to rebuild pharmaceutical manufacturing.
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX)
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is seeking stockholder approval to acquire 100% of Kashiv BioSciences’ membership interests for $375 million in cash and 28,942,108 shares of Amneal Class A common stock. Sellers are also eligible for up to $350 million in contingent cash payments tied to U.S. regulatory milestones and 25% of annual aggregate gross profits above specified hurdles for up to 12 years. The transaction, unanimously recommended by Amneal's Independent Committee and Board, is subject to stockholder approvals and regulatory clearances, with a special meeting scheduled for July 31, 2026.
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June
This article announces the filing of Form DEF 14A by Amneal Pharmaceuticals Inc Class A for June 26. It notes that the form was updated on June 26, 2026. The piece also includes standard disclaimers about the risks inherent in financial and cryptocurrency trading.
2DT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amneal Pharmaceuticals, Inc. (ticker 2DT on the Munich Stock Exchange), including analyst price targets, revenue and earnings estimates, and historical price data. It details the company's financial performance, such as recent earnings per share and revenue figures, net income, EBITDA, and employee count. The article also addresses frequently asked questions about buying 2DT stocks and its dividend policy.
2DT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amneal Pharmaceuticals, Inc. Class A (2DT) stock, including price targets from analysts ranging between 13.82 EUR and 16.41 EUR. It also details the company's past financial performance, upcoming earnings report, and other key financial metrics like revenue, net income, and EBITDA. Additionally, it addresses common questions about the stock, such as its ticker, historical high/low prices, and dividend policy.
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX)
This article provides an overview of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and details on recent earnings and revenue. The article also addresses frequently asked questions about the company's financials and future outlook, recommending comprehensive research before investing.
2DT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amneal Pharmaceuticals, Inc. Class A (ticker 2DT on Tradegate Exchange), including analyst price targets, historical stock data, and expected financial performance. Analysts have a maximum price estimate of 16.41 EUR and a minimum estimate of 13.82 EUR, with the company's next earnings report scheduled for August 12, 2026. The report also details past earnings, revenue, net income, and provides answers to frequently asked questions about the stock.
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com
Amneal Pharmaceuticals (AMRX) stock has reached a new 52-week high of $16.62, marking a 103.14% increase over the past year. This milestone follows impressive Q1 2026 financial results, including an EPS of $0.27 and revenue of $723 million, and recent FDA approval for its romidepsin injection solution. The company also announced positive interim data from its Phase 4 ELEVATE-PD study for CREXONT, a Parkinson’s disease treatment.
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD
Amneal Pharmaceuticals stock reached a 52-week high of $16.62, currently trading at $16.64 with a $5.31 billion market capitalization, reflecting a 103.14% increase over the past year. This surge is fueled by strong investor confidence, impressive Q1 2026 financial results, and positive developments like FDA approval for romidepsin and promising interim data from the CREXONT Phase 4 study for Parkinson’s disease. Despite trading above its Fair Value, the company maintains a "GREAT" Financial Health score on InvestingPro, highlighting its resilience and growth potential.
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Amneal Pharmaceuticals (AMRX) has experienced a significant rally, with its stock price closing at US$16.21. Despite this, an independent intrinsic value estimate suggests the stock is currently undervalued by about 6%, with a consensus analyst price target of $17.25. However, while the narrative points to undervaluation based on growth and profitability assumptions, the company faces pressures from a competitive generics market and substantial debt, and its P/E ratio appears high compared to peers, creating mixed signals for investors.
Top 3 Health Care Stocks That May Collapse This Quarter
The article identifies three healthcare stocks—Cardinal Health, TG Therapeutics, and Amneal Pharmaceuticals—that may be overbought according to the Relative Strength Index (RSI) as of June 15, 2026. Despite recent positive news and stock gains for all three companies, their high RSI values (above 70) suggest they could be due for a correction. The article emphasizes the RSI as a key momentum indicator for short-term trading decisions.
Amneal Pharmaceuticals (AMRX) Is Up 19.0% After CREXONT Data And New CGT Oncology Approval - What's Changed
Amneal Pharmaceuticals (AMRX) recently saw a 19.0% stock increase following positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease and FDA approval for its romidepsin injection for cutaneous T-cell lymphoma. These developments reinforce the company's strategy to expand into branded and complex therapies, moving beyond its U.S. generics business. Investors are encouraged to assess how these advancements, alongside ongoing generic pricing pressures, will influence Amneal's long-term performance and market valuation.
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD
Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $15.44, experiencing an 88% increase over the past year. This surge is attributed to the company's strong financial performance, including exceeding Q1 2026 earnings and revenue expectations, and key product developments like FDA approval for romidepsin injection and positive interim results for its Parkinson's drug CREXONT. InvestingPro rates the company's financial health as "GREAT."
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com
Amneal Pharmaceuticals Inc. Class A stock reached a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, reflecting an 88% increase over the past year. This surge is attributed to the company's strong financial health and recent positive developments, including exceeding Q1 2026 earnings and revenue expectations, FDA approval for its romidepsin injection, and positive interim results from its CREXONT Parkinson's drug study. InvestingPro analysis suggests the stock is trading near its Fair Value, and the company has a "GREAT" financial health score.
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com
Amneal Pharmaceuticals (AMRX) stock recently hit a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, representing an 88% increase over the past year. This surge reflects strong investor confidence and the company's "GREAT" financial health score, according to InvestingPro. The company also reported strong Q1 2026 financial results, surpassing EPS and revenue expectations, and secured FDA approval for a new romidepsin injection solution, alongside positive interim results for its Parkinson's drug, CREXONT.
